Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis.
暂无分享,去创建一个
P Kapeller | A J Thompson | A. Thompson | D. Miller | D. Miller | M. McLean | D. Chard | C. Griffin | P. Kapeller | R. Kapoor | D H Miller | D T Chard | M A McLean | C M Griffin | R Kapoor | A. Thompson | D. Miller
[1] Hans Lassmann,et al. Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology , 1997, Annals of neurology.
[2] Stephen M. Rao,et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. , 1999, Brain : a journal of neurology.
[3] J Star-Lack,et al. High spatial resolution 1H‐MRSI and segmented MRI of cortical gray matter and subcortical white matter in three regions of the human brain , 1999, Magnetic resonance in medicine.
[4] R. Rudick,et al. Neurological disability correlates with spinal cord axonal loss and reduced N‐acetyl aspartate in chronic multiple sclerosis patients , 2000, Annals of neurology.
[5] O. Ciccarelli,et al. Magnetic resonance outcome of new enhancing lesions in patients with relapsing‐remitting multiple sclerosis , 1999, European Journal of Neurology.
[6] M W Weiner,et al. 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS , 2000, Multiple sclerosis.
[7] M Rovaris,et al. Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. , 2000, AJNR. American journal of neuroradiology.
[8] F. Palmer,et al. Differences in the metabolism of inositol and phosphoinositides by cultured cells of neuronal and glial origin. , 1989, Biochimica et biophysica acta.
[9] B E Kendall,et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. , 1988, Brain : a journal of neurology.
[10] I. Allen,et al. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis , 1979, Journal of the Neurological Sciences.
[11] G J Barker,et al. Quantitative analysis of short echo time 1H‐MRSI of cerebral gray and white matter , 2000, Magnetic resonance in medicine.
[12] S. Reingold,et al. Defining the clinical course of multiple sclerosis , 1996, Neurology.
[13] F Barkhof,et al. Neuronal damage in T1‐hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy , 1999, Annals of neurology.
[14] R. Bakshi,et al. Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. , 2001, Archives of neurology.
[15] P M Matthews,et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. , 1998, Brain : a journal of neurology.
[16] G. Barker,et al. Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations , 2000, Journal of neurology, neurosurgery, and psychiatry.
[17] M Rovaris,et al. Lesion load quantification on fast-FLAIR, rapid acquisition relaxation-enhanced, and gradient spin echo brain MRI scans from multiple sclerosis patients. , 1999, Magnetic resonance imaging.
[18] Karl J. Friston,et al. Voxel-Based Morphometry—The Methods , 2000, NeuroImage.
[19] G. Barker,et al. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis , 1997, Journal of neurology, neurosurgery, and psychiatry.
[20] D. Gronwall. Paced Auditory Serial-Addition Task: A Measure of Recovery from Concussion , 1977, Perceptual and motor skills.
[21] D. Leibfritz,et al. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. , 1993, Developmental neuroscience.
[22] P M Matthews,et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. , 2001, Archives of neurology.
[23] M. Wyss,et al. Creatine and creatinine metabolism. , 2000, Physiological reviews.
[24] J. Coyle,et al. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies , 1991, Neuroscience.
[25] J. Taubenberger,et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis , 1993, Annals of neurology.
[26] G J Barker,et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. , 1994, Brain : a journal of neurology.
[27] K. Bhakoo,et al. In Vitro Expression of N‐Acetyl Aspartate by Oligodendrocytes , 2000, Journal of neurochemistry.
[28] P M Matthews,et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. , 1998, Brain : a journal of neurology.
[29] A J Thompson,et al. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. , 1999, Neurology.
[30] Henry W. Altland,et al. Regression Analysis: Statistical Modeling of a Response Variable , 1998, Technometrics.
[31] P G Webb,et al. Automated single‐voxel proton MRS: Technical development and multisite verification , 1994, Magnetic resonance in medicine.
[32] H. Nishitani,et al. Multivariate analysis of regional metabolic differences in normal ageing on localised quantitative proton MR spectroscopy , 2001, Neuroradiology.
[33] Igor D. Grachev,et al. Chemical Heterogeneity of the Living Human Brain: A Proton MR Spectroscopy Study on the Effects of Sex, Age, and Brain Region , 2000, NeuroImage.
[34] J S Wolinsky,et al. Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging , 2001, Multiple sclerosis.
[35] J. Frahm,et al. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS , 1998, Magnetic resonance in medicine.
[36] W Steinbrich,et al. Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. , 2000, AJNR. American journal of neuroradiology.
[37] Nikos Evangelou,et al. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis , 2000, Annals of neurology.
[38] F. Barkhof,et al. Cortical lesions in multiple sclerosis. , 1999, Brain : a journal of neurology.
[39] P. Narayana,et al. Relative Concentrations of Proton MR Visible Neurochemicals in Gray and White Matter in Human Brain , 1995, Magnetic resonance in medicine.
[40] E. Cabanis,et al. Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis , 1999, Neurology.
[41] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[42] R G Shulman,et al. In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[43] M W Weiner,et al. Region and tissue differences of metabolites in normally aged brain using multislice 1H magnetic resonance spectroscopic imaging , 2001, Magnetic resonance in medicine.
[44] J. Frahm,et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. , 1999, AJNR. American journal of neuroradiology.
[45] G. Barker,et al. The effect of section thickness on MR lesion detection and quantification in multiple sclerosis. , 1998, AJNR. American journal of neuroradiology.
[46] G J Barker,et al. A (1)H magnetic resonance spectroscopy study of aging in parietal white matter: implications for trials in multiple sclerosis. , 2000, Magnetic resonance imaging.
[47] S. Blüml,et al. Developmental changes in choline‐ and ethanolamine‐containing compounds measured with proton‐decoupled 31P MRS in in vivo human brain , 1999, Magnetic resonance in medicine.
[48] D. Goodkin,et al. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. , 1988, Archives of physical medicine and rehabilitation.
[49] Y. Boulanger,et al. Role of phospholipase A2 on the variations of the choline signal intensity observed by 1H magnetic resonance spectroscopy in brain diseases 1 1 Published on the World Wide Web on 10 August 2000. , 2000, Brain Research Reviews.
[50] B. Trapp,et al. N‐acetylaspartate is an axon‐specific marker of mature white matter in vivo: A biochemical and immunohistochemical study on the rat optic nerve , 2002, Annals of neurology.
[51] P. Matthews,et al. Chemical pathology of acute demyelinating lesions and its correlation with disability , 1995, Annals of neurology.
[52] Peter Kapeller,et al. Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study , 2001, Journal of Neurology.
[53] S. Provencher. Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.
[54] J S Wolinsky,et al. Serial proton magnetic resonance spectroscopic imaging, contrast‐enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis , 1998, Annals of neurology.
[55] R. Kinkel,et al. Axonal loss in normal-appearing white matter in a patient with acute MS , 2001, Neurology.
[56] A J Thompson,et al. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.
[57] B. Brownell,et al. The distribution of plaques in the cerebrum in multiple sclerosis , 1962, Journal of neurology, neurosurgery, and psychiatry.
[58] B. Trapp,et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.
[59] D. Paty,et al. Magnetic resonance spectroscopy of multiple sclerosis: in-vivo detection of myelin breakdown products , 1993, The Lancet.
[60] M W Weiner,et al. 1H MRSI of normal appearing white matter in multiple sclerosis , 1997, Multiple sclerosis.
[61] P. Garnier,et al. N‐Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury , 2001, Journal of neurochemistry.
[62] A. Thompson,et al. A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. , 1996, Journal of neurology, neurosurgery, and psychiatry.
[63] Geoff J. M. Parker,et al. 1H Magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis , 1999, Journal of Neurology.
[64] D. L. Collins,et al. Statistics for Investigation of Multimodal MR Imaging Data and an Application to Multiple Sclerosis Patients , 1996, NMR in biomedicine.
[65] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.